Bamco Inc. NY Trims Stake in Vertex Pharmaceuticals

Institutional investor reduces holdings in pharmaceutical company by over 40%

Mar. 17, 2026 at 7:35am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an investment management firm, has reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 42.2% in the third quarter, according to a recent SEC filing. The firm now owns 5,200 shares of the pharmaceutical company's stock, down from 9,000 shares previously.

Why it matters

Vertex Pharmaceuticals is a leading biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis. Changes in institutional ownership can provide insights into investor sentiment and market expectations for the company.

The details

According to the SEC filing, Bamco Inc. NY sold 3,800 shares of Vertex Pharmaceuticals during the third quarter, reducing its total holdings to 5,200 shares. The firm's stake in Vertex was valued at $2,037,000 as of the most recent filing.

  • Bamco Inc. NY reduced its Vertex Pharmaceuticals holdings in the third quarter of 2026.

The players

Bamco Inc. NY

An investment management firm that has reduced its stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Bamco Inc. NY's Vertex Pharmaceuticals holdings could signal a shift in investor sentiment towards the company, though further analysis would be needed to determine the broader implications for Vertex's business and stock performance.